Morepen Labs.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE083A01026
  • NSEID: MOREPENLAB
  • BSEID: 500288
INR
50.95
-0.57 (-1.11%)
BSENSE

Jun 18

BSE+NSE Vol: 46.01 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Venus Remedies
Kwality Pharma
Morepen Labs.
Novartis India
SMS Pharma.
Aarti Drugs
Panacea Biotec
Solara Active
Unichem Labs.
Dishman Carbogen
Sai Parenteral's
Why is Morepen Laboratories Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0.02 times
2
Poor long term growth as Net Sales has grown by an annual rate of 8.73% and Operating profit at 0.22% over the last 5 years
3
Negative results in Mar 26
  • PBT LESS OI(Q) At Rs 14.83 cr has Fallen at -24.9% (vs previous 4Q average)
  • ROCE(HY) Lowest at 7.60%
  • PAT(Q) At Rs 15.74 cr has Fallen at -17.4% (vs previous 4Q average)
4
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 17-Jun-26
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST and OBV
5
With ROE of 5.7, it has a Expensive valuation with a 2.3 Price to Book Value
  • The stock is trading at a fair value compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -17.99%, its profits have fallen by -39.3%
6
Despite the size of the company, domestic mutual funds hold only 0% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Morepen Labs. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Morepen Labs. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Morepen Labs.
-18.22%
-0.40
44.55%
Sensex
-5.14%
-0.39
13.26%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
8.73%
EBIT Growth (5y)
0.22%
EBIT to Interest (avg)
13.59
Debt to EBITDA (avg)
0.49
Net Debt to Equity (avg)
0.09
Sales to Capital Employed (avg)
1.84
Tax Ratio
20.25%
Dividend Payout Ratio
9.29%
Pledged Shares
0
Institutional Holding
2.85%
ROCE (avg)
13.03%
ROE (avg)
10.00%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
39
Industry P/E
34
Price to Book Value
2.26
EV to EBIT
32.95
EV to EBITDA
23.39
EV to Capital Employed
2.16
EV to Sales
1.63
PEG Ratio
NA
Dividend Yield
0.39%
ROCE (Latest)
6.55%
ROE (Latest)
5.75%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company
CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 68.83 cr

NET SALES(Q)

Highest at Rs 484.72 cr

-15What is not working for the Company
PBT LESS OI(Q)

At Rs 14.83 cr has Fallen at -24.9% (vs previous 4Q average

ROCE(HY)

Lowest at 7.60%

PAT(Q)

At Rs 15.74 cr has Fallen at -17.4% (vs previous 4Q average

OPERATING PROFIT TO NET SALES (Q)

Lowest at 5.04%

NON-OPERATING INCOME(Q)

is 36.32 % of Profit Before Tax (PBT

Loading Valuation Snapshot...
Here's what is working for Morepen Labs.
Net Sales - Quarterly
Highest at Rs 484.72 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Cash and Cash Equivalents - Half Yearly
Highest at Rs 68.83 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Morepen Labs.
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 14.83 cr has Fallen at -24.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 19.76 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 15.74 cr has Fallen at -17.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 19.06 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Operating Profit Margin - Quarterly
Lowest at 5.04%
in the last five quarters
MOJO Watch
Company's efficiency has deteriorated

Operating Profit to Sales

Non Operating Income - Quarterly
is 36.32 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT

Non Operating Income - Quarterly
Highest at Rs 8.46 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income